Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NARATRIPTAN vs ACULAR LS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin 5-HT1B/1D receptor agonist; binds to these receptors on intracranial blood vessels and trigeminal sensory neurons, causing vasoconstriction and inhibition of neuropeptide release, thereby reducing migraine-related inflammation and pain.
Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.
Acute treatment of migraine with or without aura in adults
FDA: Treatment of postoperative inflammation in patients who have undergone cataract surgery,Off-label: Relief of ocular pain, photophobia, and inflammation associated with corneal abrasion or refractive surgery
2.5 mg orally at onset of migraine; may repeat after 4 hours if headache recurs, maximum 5 mg per day.
1 drop in the affected eye(s) four times daily
Terminal elimination half-life is approximately 5–6 hours (range 4–8 hours), supporting a twice-daily dosing interval for acute migraine treatment and allowing once-daily dosing for menstrual migraine prophylaxis.
The terminal elimination half-life is approximately 1.8 hours (range 1.2–2.5 hours) following topical ocular administration. This short half-life is consistent with rapid clearance from the systemic circulation.
Hepatic via cytochrome P450 (CYP) enzymes, primarily CYP3A4, with minor contribution from other isoforms. Metabolites are inactive.
Primarily hepatic via CYP2C9; undergoes glucuronidation and oxidation to inactive metabolites.
Renal: ~50% (metabolites and unchanged drug); Fecal: ~30%; Biliary: minor; unchanged naratriptan accounts for <10% of urinary recovery.
Renal excretion of metabolites and unchanged drug accounts for approximately 26% of the dose. Fecal excretion accounts for approximately 74% of the dose, primarily as metabolites.
~29% bound, primarily to albumin.
Ketorolac is highly protein bound, approximately 99% bound to plasma proteins, primarily albumin.
Approximately 2.4 L/kg (range 1.8–3.0 L/kg), consistent with extensive tissue distribution beyond plasma.
The volume of distribution is approximately 0.12 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral: 74% (range 63–95%); subcutaneous: ~100% (but not marketed).
Ophthalmic bioavailability is approximately 2% of the administered dose due to extensive nasolacrimal drainage and systemic absorption. Oral bioavailability of ketorolac is approximately 80-100%, but this route is not used for ophthalmic formulations.
No dose adjustment recommended; however, use with caution in severe renal impairment (Cr Cl <15 m L/min) due to limited data.
No dosage adjustment required for renal impairment
Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), maximum dose is 2.5 mg per day; do not exceed single dose of 2.5 mg.
No dosage adjustment required for hepatic impairment but use with caution in severe hepatic disease due to potential for increased systemic exposure
Safety and efficacy not established in patients under 18 years; no approved pediatric dosing guidelines.
Safety and efficacy in pediatric patients below 2 years of age have not been established; for children 2 years and older, same as adult dosing
Use with caution due to potential for reduced hepatic and renal function; no specific dose adjustment recommended, but start at low end of dosing range (2.5 mg).
No specific dose adjustment recommended; use with caution due to increased incidence of age-related ocular conditions
Naratriptan is contraindicated in patients with ischemic heart disease or coronary artery vasospasm due to risk of myocardial ischemia/infarction and cerebrovascular events.
None
Cardiac events: risk of myocardial ischemia, infarction, and arrhythmias,Cerebrovascular events: stroke, subarachnoid hemorrhage,Serotonin syndrome: especially with concomitant serotonergic drugs,Medication overuse headache: chronic use can lead to daily headaches,Severe hepatic impairment: reduce dose or avoid,Severe renal impairment: contraindicated
Increased risk of bleeding and bleeding-related adverse events due to platelet inhibition,May prolong bleeding time,Cross-sensitivity with aspirin and other NSAIDs,Caution in patients with prior history of corneal epithelial defects or ocular surgery,Not for intraocular injection
Ischemic heart disease (angina, history of MI, silent ischemia),Coronary artery vasospasm (Prinzmetal's angina),History of stroke or transient ischemic attack,Uncontrolled hypertension,Hemiplegic or basilar migraine,Severe hepatic impairment (Child-Pugh C),Severe renal impairment (Cr Cl <15 m L/min),Concurrent use of ergotamine derivatives or other 5-HT1 agonists within 24 hours,Hypersensitivity to naratriptan or any component
Hypersensitivity to ketorolac tromethamine or any component of the formulation,Patients with active peptic ulcer disease, recent GI bleeding, or perforation,Patients with advanced renal disease or at risk for renal failure,Patients with known history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
No significant food interactions. However, grapefruit juice may theoretically increase naratriptan exposure via CYP1A2 inhibition; avoid concurrent intake of large quantities. Alcohol may exacerbate migraine symptoms and should be avoided during an attack.
No known food interactions for ophthalmic ketorolac. However, maintain good hydration and nutrition to support corneal healing.
FDA Pregnancy Category C. Animal studies show fetal toxicity (increased resorptions, skeletal anomalies) at maternotoxic doses. No adequate human studies. Avoid in first trimester unless benefit outweighs risk. Second/third trimester: limited data; use only if clearly needed.
Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during organogenesis resulted in increased embryofetal mortality, delayed ossification, and increased incidence of skeletal abnormalities at doses less than the maximum recommended human ophthalmic dose. However, systemic exposure following ocular administration is very low. NSAIDs are generally avoided during pregnancy, especially in the third trimester, due to the risk of premature closure of the ductus arteriosus and oligohydramnios. The risk is considered low for ophthalmic use but should be used only if clearly needed.
Unknown if excreted in human milk; M/P ratio not established. Due to low molecular weight (335.46 g/mol), excretion is possible. Caution advised; monitor infant for adverse effects (e.g., drowsiness, diarrhea).
It is not known whether ketorolac is excreted in human milk after ophthalmic administration. Systemic levels are low, and following oral administration, ketorolac is excreted in breast milk at low concentrations (M/P ratio approximately 0.37). Due to the potential for adverse effects on the nursing infant, caution should be exercised. The low systemic absorption likely poses minimal risk.
No specific pharmacokinetic data in pregnancy. Increased plasma volume and renal clearance in pregnancy may reduce drug exposure; however, lack of safety data precludes dose adjustments. Use lowest effective dose for shortest duration.
No dosing adjustments are necessary for ophthalmic use during pregnancy due to negligible systemic absorption. Standard dosing (1 drop in the affected eye(s) four times daily) is recommended. Systemic NSAIDs may require dose adjustment due to increased volume of distribution and renal changes, but this does not apply to topical ocular ketorolac.
Naratriptan has a longer half-life (~6 hours) and higher oral bioavailability (70%) compared to sumatriptan, making it suitable for patients with prolonged migraine attacks or those requiring sustained relief. It is contraindicated in patients with a history of ischemic heart disease, cerebrovascular disease, or uncontrolled hypertension due to vasoconstrictive effects. Use within 4 hours of migraine onset for optimal efficacy; do not use for prophylaxis. Monitor for serotonin syndrome when co-administered with other serotonergic drugs.
ACULAR LS (ketorolac tromethamine ophthalmic solution 0.4%) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the reduction of ocular pain and photophobia following corneal refractive surgery. Use with caution in patients with known bleeding tendencies or those on anticoagulants due to increased risk of ocular bleeding. Avoid concurrent use with other NSAIDs or steroids to minimize corneal adverse effects. Monitor for corneal epithelial breakdown or delayed healing.
Take naratriptan at the first sign of migraine headache; do not use to prevent migraines.,Do not exceed one tablet (2.5 mg) within 24 hours; do not take more than 2 tablets in any 24-hour period.,Seek emergency medical attention if you experience chest pain, shortness of breath, or sudden severe abdominal pain after taking this medication.,Inform your doctor if you have heart disease, high blood pressure, liver or kidney problems, or if you are pregnant or breastfeeding.,Avoid using naratriptan within 24 hours of other triptans or ergotamine-containing medications.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 10 minutes before reinserting.,Use only in the affected eye(s) as prescribed; do not use for longer than directed.,Temporary stinging or burning may occur upon instillation.,Report any persistent pain, redness, or visual changes to your doctor immediately.,Avoid driving or operating machinery if vision is blurred after use.
"Concurrent use of naratriptan, a serotonin 5-HT1B/1D receptor agonist, with dapiprazole, an alpha-1 adrenergic receptor antagonist, may lead to additive vasoconstrictive effects on coronary, cerebral, and peripheral vasculature. This synergy increases the risk of severe adverse events such as myocardial ischemia, hypertension, or cerebrovascular complications due to unopposed vasoconstriction from naratriptan and potential reflex sympathetic activation from dapiprazole's alpha blockade. Particularly in patients with underlying cardiovascular risk factors, this combination can precipitate hypertensive crises or ischemic events."
"Concomitant use of naratriptan, a serotonin 5-HT1B/1D receptor agonist, and clozapine, an atypical antipsychotic with potent 5-HT2A receptor antagonism, may lead to additive serotonergic effects, increasing the risk of serotonin syndrome. This potentially life-threatening condition is characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients, especially those on higher doses or with other serotonergic agents, should be closely monitored for symptoms such as hyperthermia, rigidity, myoclonus, and tachycardia."
"Concomitant use of naratriptan, a 5-HT1B/1D receptor agonist, with bromocriptine, a dopamine D2 receptor agonist and ergot alkaloid derivative, may result in additive vasoconstriction due to synergistic stimulation of serotonin and dopamine receptors on vascular smooth muscle. This can lead to an increased risk of hypertensive crises, coronary artery vasospasm, myocardial ischemia, or cerebral ischemia, particularly in patients with underlying cardiovascular disease. Additionally, both drugs can elevate serotonin levels centrally, potentially raising the risk of serotonin syndrome, characterized by agitation, hyperthermia, and neuromuscular abnormalities."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NARATRIPTAN vs ACULAR LS, answered by our medical review team.
NARATRIPTAN is a 5-HT1 Agonist that works by Selective serotonin 5-HT1B/1D receptor agonist; binds to these receptors on intracranial blood vessels and trigeminal sensory neurons, causing vasoconstriction and inhibition of neuropeptide release, thereby reducing migraine-related inflammation and pain.. ACULAR LS is a NSAID Ophthalmic that works by Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NARATRIPTAN and ACULAR LS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NARATRIPTAN is: 2.5 mg orally at onset of migraine; may repeat after 4 hours if headache recurs, maximum 5 mg per day.. The standard adult dose of ACULAR LS is: 1 drop in the affected eye(s) four times daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NARATRIPTAN and ACULAR LS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NARATRIPTAN is classified as Category D/X. FDA Pregnancy Category C. Animal studies show fetal toxicity (increased resorptions, skeletal anomalies) at maternotoxic doses. No adequate human studies. Avoid in first trimester . ACULAR LS is classified as Category C. Ketorolac tromethamine, the active ingredient in ACULAR LS, is a nonsteroidal anti-inflammatory drug (NSAID). In animal reproduction studies, administration of ketorolac during org. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.